Matches in SemOpenAlex for { <https://semopenalex.org/work/W2409960912> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W2409960912 endingPage "52" @default.
- W2409960912 startingPage "47" @default.
- W2409960912 abstract "The low-dose oral standard antiandrogen treatment with cyproterone acetate (CPA), Diane, is frequently associated with unsatisfactory results regarding moderate to severe seborrhoea/acne/acne and/or mild to moderate hirsutism. This multicenter double-blind study (n = 164) was, therefore, initiated to analyze the effectiveness of a medium dose oral regimen, i.e. the addition of 10 mg of CPA during the first 15 days of the Diane-treatment cycle. Good or satisfactory results after 3, 6, 9 and 12 months were observed in 61, 81, 95 and 97% of patients with moderate to severe seborrhoea (n = 79); in 53, 95, 98 and 100% of patients with moderate to severe acne (n = 62); and in 10, 28, 45 and 55% of patients with mild to moderate hirsutism (n = 89), respectively. The regression of moderate facial hirsutism and severe facial acne occurred faster and was more complete under the medium-dose than with the low-dose regimen. Side effects corresponded to those of conventional oral contraceptives except for a higher frequency of mastodynia. Both regimens caused a significant suppression of plasma dehydroepiandrosterone sulfate, while testosterone, triiodothyronine and thyroxine were lowered insignificantly. In contrast, cortisol, prolactin and insulin increased significantly. The extent of these changes did not differ in both modes of treatment. The medium-dose regimen (total dosage per cycle: 192 mg of CPA) is more effective than the low-dose regimen (42 mg of CPA per cycle) in the treatment of patients with moderate hyperandrogenism who do not require the high-dose oral standard antiandrogen therapy (1000 mg of CP A per cycle)." @default.
- W2409960912 created "2016-06-24" @default.
- W2409960912 creator A5030162492 @default.
- W2409960912 creator A5044263836 @default.
- W2409960912 date "1984-01-01" @default.
- W2409960912 modified "2023-10-17" @default.
- W2409960912 title "Mittelhochdosierte orale Cyproteronacetat-Therapie bei Frauen mit mittelgradig ausgeprägten Androgenisierungserscheinungen" @default.
- W2409960912 doi "https://doi.org/10.1055/s-2008-1036425" @default.
- W2409960912 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/6230282" @default.
- W2409960912 hasPublicationYear "1984" @default.
- W2409960912 type Work @default.
- W2409960912 sameAs 2409960912 @default.
- W2409960912 citedByCount "8" @default.
- W2409960912 countsByYear W24099609122015 @default.
- W2409960912 countsByYear W24099609122016 @default.
- W2409960912 crossrefType "journal-article" @default.
- W2409960912 hasAuthorship W2409960912A5030162492 @default.
- W2409960912 hasAuthorship W2409960912A5044263836 @default.
- W2409960912 hasConcept C126322002 @default.
- W2409960912 hasConcept C126894567 @default.
- W2409960912 hasConcept C16005928 @default.
- W2409960912 hasConcept C2776371013 @default.
- W2409960912 hasConcept C2777155358 @default.
- W2409960912 hasConcept C2777391703 @default.
- W2409960912 hasConcept C2777673923 @default.
- W2409960912 hasConcept C2777911890 @default.
- W2409960912 hasConcept C2779306644 @default.
- W2409960912 hasConcept C2779322244 @default.
- W2409960912 hasConcept C2780186808 @default.
- W2409960912 hasConcept C2781413609 @default.
- W2409960912 hasConcept C29456083 @default.
- W2409960912 hasConcept C3018442814 @default.
- W2409960912 hasConcept C71315377 @default.
- W2409960912 hasConcept C71924100 @default.
- W2409960912 hasConcept C90924648 @default.
- W2409960912 hasConceptScore W2409960912C126322002 @default.
- W2409960912 hasConceptScore W2409960912C126894567 @default.
- W2409960912 hasConceptScore W2409960912C16005928 @default.
- W2409960912 hasConceptScore W2409960912C2776371013 @default.
- W2409960912 hasConceptScore W2409960912C2777155358 @default.
- W2409960912 hasConceptScore W2409960912C2777391703 @default.
- W2409960912 hasConceptScore W2409960912C2777673923 @default.
- W2409960912 hasConceptScore W2409960912C2777911890 @default.
- W2409960912 hasConceptScore W2409960912C2779306644 @default.
- W2409960912 hasConceptScore W2409960912C2779322244 @default.
- W2409960912 hasConceptScore W2409960912C2780186808 @default.
- W2409960912 hasConceptScore W2409960912C2781413609 @default.
- W2409960912 hasConceptScore W2409960912C29456083 @default.
- W2409960912 hasConceptScore W2409960912C3018442814 @default.
- W2409960912 hasConceptScore W2409960912C71315377 @default.
- W2409960912 hasConceptScore W2409960912C71924100 @default.
- W2409960912 hasConceptScore W2409960912C90924648 @default.
- W2409960912 hasIssue "01" @default.
- W2409960912 hasLocation W24099609121 @default.
- W2409960912 hasLocation W24099609122 @default.
- W2409960912 hasOpenAccess W2409960912 @default.
- W2409960912 hasPrimaryLocation W24099609121 @default.
- W2409960912 hasRelatedWork W108309870 @default.
- W2409960912 hasRelatedWork W1994116540 @default.
- W2409960912 hasRelatedWork W2073187238 @default.
- W2409960912 hasRelatedWork W2115225759 @default.
- W2409960912 hasRelatedWork W2138788529 @default.
- W2409960912 hasRelatedWork W2146319242 @default.
- W2409960912 hasRelatedWork W2158129725 @default.
- W2409960912 hasRelatedWork W2402289928 @default.
- W2409960912 hasRelatedWork W2609651499 @default.
- W2409960912 hasRelatedWork W2918979897 @default.
- W2409960912 hasVolume "44" @default.
- W2409960912 isParatext "false" @default.
- W2409960912 isRetracted "false" @default.
- W2409960912 magId "2409960912" @default.
- W2409960912 workType "article" @default.